Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.

Abstract: The present invention relates to a composition for anti-green algae containing water-soluble free amine chitosan having the anti-algae activity against water-bloom forming algae as an active ingredient and a method for preparing the same. Particularly, the water-soluble free amine chitosan of the present invention can kill directly water-bloom forming algae, suggesting that it has excellent anti-green algae activity to inhibit water-bloom, and is non-toxic to freshwater organism cells. Therefore, the composition for anti-green algae containing the said water-soluble free amine chitosan as an active ingredient can be efficiently used as a safe anti-green algae composition applicable in the freshwater ecosystem including solidified dam, reservoir, lake, golf course water hazard, pond, freshwater fish farm, and fishing spot.

Abstract: An herbicide composition available as a concentrate for dilution with water or a ready-to-use oil-in-water emulsion which has a significantly reduced amount of active ingredient of a broadleaf herbicide. The composition combines the reduced amount of herbicide in a mixture of oil and emulsifier.

Abstract: A method of treating cancer using ketogenic diet, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient.

Abstract: The present application describes personal care compositions, comprising a surfactant and agglomerated cellulose derivative, provided that the cellulose derivative has been agglomerated with a sufficient amount of carboxymethylcellulose as binder, and provided that the personal care composition is substantially free of glyoxal.

Abstract: Disclosed are devices, systems, and methods for producing broad spectrum disinfectants using a colloidal suspension of chlorine dioxide in deionized water, and more particularly, producing chlorine dioxide compositions that clean, disinfect and/or sterilize in one step with no harmful byproducts.

Abstract: The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.

Abstract: Composites and methods of producing a mouldable bone substitute are described. A scaffold for bone growth comprises nanocrystalline hydroxyapatite (HA), a bioresorbable plasticizer, and a biodegradable polymer. Plasticizers of the invention include oleic acid, tocopherol, eugenol, 1,2,3-triacetoxypropane, monoolein, and octyl-beta-D-glucopyranoside. Polymers of the invention include poly(caprolactone), poly(D,L-Lactic acid), and poly(glycolide-co lactide). Methods of regulating porosity, hardening speed, and shapeability are also described. Composites and methods are described using nanocrystalline HA produced with and without amino acids. The scaffold for bone growth described herein displays increased strength and shapeability.

Abstract: The present invention concerns a topical, cosmetic or pharmaceutical preparation containing a combination of 3 or 4 solar filters comprising:—one or two UVA filters to obtain a critical wavelength>370 nm, chosen from among: (i)—5,6,5,6-tetraphenyl-3, 3?-(1,4-phenylene)-bis[1,2,4]triazine; (ii) 1,1?-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone; (iii)—Butyl Methoxydibenzoylmethane (BMDBM), in a quantity less than 2% by weight with regard to the total weight of said composition; (iv)—Hexyl-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, -2,4-Bis[4-(2-ethyl-hexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine=(BEMT), —one or two filters chosen from among UVB filters, except octocrylene, PABA and ethylhexyl methoxycinnamate, said composition also containing a pharmaceutically or cosmetically acceptable excipient.

Abstract: The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

Abstract: Disclosed is a tablet containing anhydrous calcium hydrogen phosphate, granules (A) which contain sugars, and granules (B) which contain nuclear particles having a diameter of 10-500?m, medicine and a film coating, and which have a particle diameter of 700?m or less. The present invention enables tablet-making difficulties during the manufacture of the tablet to be suppressed. In addition, the tablet has an appropriate hardness, an excellent disintegration time, and feels very good to ingest.

Abstract: Disclosed herein are methods of controlling undesirable vegetation in pineapple, which comprise applying to vegetation or an area adjacent the vegetation or applying to soil to prevent the emergence or growth of vegetation (a) penoxsulam or an agriculturally acceptable salt thereof. The methods can further comprise applying (b) a second pesticide or an agriculturally acceptable salt or ester thereof to the vegetation or the area adjacent the vegetation or to the soil adjacent thereto. In some embodiments, (b) includes an ACCase inhibitor such as cyhalofop-butyl, haloxyfop-P-methyl, fluazifop-P-butyl, or combinations thereof.

Abstract: The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

Abstract: Pharmaceutical formulations for the treatment of Helicobacter pylori infection and duodenal ulcer disease and methods of preparation and medicinal use of at least one proton pump inhibitor and at least two different antibiotics within the same solid oral dosage form, whereby at least one antibiotic is encapsulated independently from at least one other antibiotic within this solid oral dosage form.

Abstract: A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.

Abstract: A composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in needle form, pellet form or powder form and constitutes between about 1% and about 10% by weight of the pesticide composition. The composition may be applied to an area inhabited by cockroaches, including, but not limited to, in crevices, cracks, corners, wall and floor junctures or other enclosed or partially enclosed areas of a structure.

Abstract: The present invention relates to a herbicidal composition which comprises pyroxasulfone along with any one or more of glyphosate, glufosinate, or their salts. The herbicidal composition may also comprise one or more of an ALS inhibitor, a PPO inhibitor, an auxine, an HPPD inhibitor, a PDS inhibitor, a PSII inhibitor, a microtublin inhibitor or a VLCFA inhibitor.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: The present invention includes compositions and methods for the treatment of plants against pathogens, elimination of insects and to increase the shelf-life of fruits and vegetables that includes coating the plant with undiluted aloe vera gel.

Abstract: An emulsifiable concentrate for emulsified phytosanitary composition, including more than 90% by weight of at least one mixture of hydrocarbons having a distillation cut greater than 250° C., less than 20% by weight of n-paraffins and less than 1% aromatics, and from 1 to 4% by weight of a mixture of at least two surfactants TA1 and TA2, such that TA2 is more hydrophobic than TA1, the HLB of the mixture of which varies from 6 to 10.